GSK’s (GSK) “Hold” Rating Reiterated at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reaffirmed their hold rating on shares of GSK (LON:GSK) in a research note released on Tuesday morning,Digital Look reports. The brokerage currently has a GBX 2,000 target price on the stock.

Several other analysts have also recently weighed in on GSK. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 2,500 price target on shares of GSK in a report on Wednesday, July 29th. Citigroup cut their price objective on GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of GBX 2,048.57.

GSK Trading Up 1.1%

Shares of GSK stock opened at GBX 1,936.50 on Tuesday. The company has a market capitalization of £77.57 billion, a PE ratio of 13.63, a price-to-earnings-growth ratio of 1.24 and a beta of 0.30. GSK has a 52-week low of GBX 1,288.61 and a 52-week high of GBX 2,282. The business’s fifty day moving average is GBX 1,938.41 and its 200 day moving average is GBX 1,994.24. The company has a debt-to-equity ratio of 103.36, a quick ratio of 0.73 and a current ratio of 0.82.

GSK (LON:GSK) last posted its earnings results on Tuesday, July 28th. The company reported GBX 10.80 EPS for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. On average, equities research analysts anticipate that GSK will post 175.980975 EPS for the current fiscal year.

Insider Activity

In other news, insider Jeannie Lee bought 802 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was bought at an average price of GBX 5,069 per share, for a total transaction of £40,653.38. Also, insider Vishal Sikka bought 1,266 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average price of GBX 5,069 per share, with a total value of £64,173.54. In the last three months, insiders have bought 3,625 shares of company stock worth $13,495,004. 0.20% of the stock is currently owned by insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.